VRDN
Viridian Therapeutics Inc

9,435
Mkt Cap
$3.14B
Volume
1.39M
52W High
$34.29
52W Low
$9.90
PE Ratio
-9.36
VRDN Fundamentals
Price
$33.06
Prev Close
$32.93
Open
$32.60
50D MA
$31.48
Beta
1.04
Avg. Volume
1.43M
EPS (Annual)
-$3.07
P/B
8.66
Rev/Employee
$2,111.89
Loading...
Loading...
News
all
press releases
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have earned an average rating of "Moderate Buy" from the fifteen analysts that are covering the stock, Marketbeat.com reports...
MarketBeat·4d ago
News Placeholder
More News
News Placeholder
SG Americas Securities LLC Acquires 49,981 Shares of Viridian Therapeutics, Inc. $VRDN
SG Americas Securities LLC grew its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 411.8% in the third quarter, according to the company in its most recent Form 13F filing...
MarketBeat·10d ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Reaches New 52-Week High - Still a Buy?
Viridian Therapeutics (NASDAQ:VRDN) Sets New 52-Week High - Still a Buy...
MarketBeat·12d ago
News Placeholder
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today...
Business Wire·18d ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Price Target Lowered to $40.00 at Truist Financial
Truist Financial cut their price objective on shares of Viridian Therapeutics from $41.00 to $40.00 and set a "buy" rating on the stock in a research report on Thursday...
MarketBeat·19d ago
News Placeholder
Viridian Therapeutics Prepares for Transformational 2026
Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today...
Business Wire·21d ago
News Placeholder
Jennifer Tousignant Sells 2,272 Shares of Viridian Therapeutics (NASDAQ:VRDN) Stock
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) insider Jennifer Tousignant sold 2,272 shares of the business's stock in a transaction on Wednesday, December 31st. The stock was sold at...
MarketBeat·24d ago
News Placeholder
Viridian Therapeutics (NASDAQ:VRDN) Insider Sells $70,795.52 in Stock
Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) insider Jennifer Tousignant sold 2,272 shares of Viridian Therapeutics stock in a transaction that occurred on Wednesday, December 31st...
MarketBeat·24d ago
News Placeholder
Simplify Asset Management Inc. Purchases Shares of 50,000 Viridian Therapeutics, Inc. $VRDN
Simplify Asset Management Inc. acquired a new position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) during the third quarter, according to the company in its most recent Form...
MarketBeat·28d ago
News Placeholder
Viridian Therapeutics, Inc. (NASDAQ:VRDN) Receives Consensus Rating of "Moderate Buy" from Brokerages
Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Get Free Report) have been given an average rating of "Moderate Buy" by the thirteen ratings firms that are presently covering the company...
MarketBeat·29d ago
<
1
2
...
>

Latest VRDN News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.